Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn
Executive Summary
Boehringer Ingelheim culled its late-stage lung cancer partnership with Hanmi after spending $65m in the first year because of the rapidly changing environment in the EGFR-positive lung cancer space. The German company doesn't intend to sit around licking its olmutinib-induced wounds, though, and is still committed to the lung cancer space.
You may also be interested in...
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.
Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.
Clovis Pulls Plug On Rociletinib On Expected FDA Rejection
Clovis Oncology Inc. on May 5 disclosed the FDA notified the company to expect its application for its experimental lung cancer drug rociletinib to be rejected – something that was widely expected on Wall Street after the firm failed in April to convince a federal panel of experts to back the medicine. Clovis, which is cutting its staff by 35% in the wake of the FDA's snub, now turns its attention to its investigational ovarian cancer drug rucaparib.